// App-Quantinova.ai

2690014 : Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular AMD: CANTREAT Study One Year Results

Researchers

Presenter

  • Peter Kertes

Principal Investigators

  • Tom Sheidow

  • Geoff Williams

  • Mark Greve

  • Ivan John Galic

  • Emmanouil Rampakakis

  • Joanne Gavalakis

  • Andrea Scarino

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • Alberta Retina Consultants , Edmonton, Alberta, Canada

  • Western Univeristy, London, ON, Canada

  • Calgary Retina Consultants, Calgary, Alberta, Canada

  • Montreal Heart Institute, Montreal, Quebec, Canada

  • Novartis Pharma Canada Inc., Dorval, QC, Canada,

  • Ivey Eye Institute, London, Ontario, Canada

  • JSS Medical Research, St-Laurent, QC, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • The John and Liz Tory Eye Centre, Toronto, Ontario, Canada

  • University of Alberta Hospital, Edmonton, Alberta, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Adenosylmethionine Decarboxylase 1

Drug/Treatment

  • Ranibizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved